Biofrontera (BFRI) Net Income towards Common Stockholders (2020 - 2026)
Biofrontera (BFRI) posted quarterly Net Income towards Common Stockholders of $7.9 million for Q4 2025, up 663.9% year-over-year from $1.0 million in Q4 2024, and up 218.39% quarter-over-quarter from -$6.6 million in Q3 2025.
Biofrontera (BFRI) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Biofrontera's Net Income towards Common Stockholders history runs 6 years deep, the most recent figure standing at $7.9 million for Q4 2025.
- In Q4 2025, Net Income towards Common Stockholders rose 663.9% year-over-year to $7.9 million; the TTM figure through Dec 2025 stood at -$8.3 million (up 53.24% YoY), while the FY2025 annual figure was -$8.3 million, up 53.24% from the prior year.
- Net Income towards Common Stockholders for Q4 2025 stood at $7.9 million, up from -$6.6 million in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $7.9 million in Q4 2025, with the low at -$16.0 million in Q3 2021.
- The 5-year median for Net Income towards Common Stockholders is -$3.9 million (2021), against an average of -$4.2 million.
- The sharpest annual moves came in 2021 and 2025: Net Income towards Common Stockholders slumped 7698.39% in 2021, then surged 663.9% in 2025.
- Biofrontera's Net Income towards Common Stockholders stood at -$14.5 million in 2021, then surged by 80.8% to -$2.8 million in 2022, then soared by 226.61% to $3.5 million in 2023, then sank by 139.59% to -$1.4 million in 2024, then soared by 663.9% to $7.9 million in 2025.
- Business Quant data shows BFRI's Net Income towards Common Stockholders at $7.9 million in Q4 2025, -$6.6 million in Q3 2025, and -$5.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 710.19 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Biofrontera | 18.87 Mn | 14.16 Mn | 9.59 Mn | -604,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -604,000.00 |
| Dec 31, 2025 | 7.87 Mn |
| Sep 30, 2025 | -6.65 Mn |
| Jun 30, 2025 | -5.32 Mn |
| Mar 31, 2025 | -4.20 Mn |
| Dec 31, 2024 | -1.40 Mn |
| Sep 30, 2024 | -5.67 Mn |
| Jun 30, 2024 | -257,000.00 |
| Mar 31, 2024 | -10.44 Mn |
| Dec 31, 2023 | 3.53 Mn |
| Sep 30, 2023 | -6.34 Mn |
| Jun 30, 2023 | -9.84 Mn |
| Mar 31, 2023 | -7.48 Mn |
| Dec 31, 2022 | -2.79 Mn |
| Sep 30, 2022 | -2.57 Mn |
| Jun 30, 2022 | -850,000.00 |
| Mar 31, 2022 | 5.56 Mn |
| Dec 31, 2021 | -14.51 Mn |
| Sep 30, 2021 | -16.01 Mn |
| Jun 30, 2021 | -3.66 Mn |